Candice Sauder

Dr. Candice Sauder

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2014 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
IPIvanesa Pardo
Ivanesa Pardo
HLHeather A Lillemoe
Heather A Lillemoe
RBRachel J Blosser
Rachel J Blosser
MCMI RAN CHOI
MI RAN CHOI
CSCandice Sauder
Candice Sauder
SCSusan E Clare
Susan E Clare
Introduction: Our efforts to prevent and treat breast cancer are significantly impeded by a lack of knowledge of the biology and developmental genetics of the normal mammary gland. In order to provide the specimens that will facilitate such an understanding, The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center (KTB) was established. The KTB is, to our knowledge, the only biorepository in the world prospectively established to collect normal, healthy breast tissue from volunteer donors. As a first initiative toward a molecular understanding of the biology and developmental genetics of the normal mammary gland, the effect of the menstrual cycle and hormonal contraceptives on DNA expression in the normal breast epithelium was examined. Methods: Using normal breast tissue from 20 premenopausal donors to KTB, the changes in the mRNA of the normal breast epithelium as a function of phase of the menstrual cycle and hormonal contraception were assayed using next-generation whole transcriptome sequencing (RNA-Seq). Results: In total, 255 genes representing 1.4% of all genes were deemed to have statistically significant differential expression between the two phases of the menstrual cycle. The overwhelming majority (221; 87%) of the genes have higher expression during the luteal phase. These data provide important insights into the processes occurring during each phase of the menstrual cycle. There was only a single gene significantly differentially expressed when comparing the epithelium of women using hormonal contraception to those in the luteal phase. Conclusions: We have taken advantage of a unique research resource, the KTB, to complete the first-ever next-generation transcriptome sequencing of the epithelial compartment of 20 normal human breast specimens. This work has produced a comprehensive catalog of the differences in the expression of protein-coding genes as a function of the phase of the menstrual cycle. These data constitute the beginning of a reference data set of the normal mammary gland, which can be consulted for comparison with data developed from malignant specimens, or to mine the effects of the hormonal flux that occurs during the menstrual cycle.

29 November 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MRMilan Radovich
Milan Radovich
SCSusan E. Clare
Susan E. Clare
RARutuja Atale
Rutuja Atale
IPIvanesa Pardo
Ivanesa Pardo
BHBradley A. Hancock
Bradley A. Hancock
BSBryan P. Schneider
Bryan P. Schneider

13 February 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SBSarah B. Bateni
Sarah B. Bateni
ADAnders J. Davidson
Anders J. Davidson
MAMili Arora
Mili Arora
MDMegan E. Daly
Megan E. Daly
SSSusan L. Stewart
Susan L. Stewart
CSCandice Sauder
Candice Sauder

16 June 2023 in Annals of Surgery
Verified
Journal Article
Closed access
RMRita A. Mukhtar
Rita A. Mukhtar
HCHarrison Chau
Harrison Chau
HWHannah Woriax
Hannah Woriax
MPMara D.O. Piltin
Mara D.O. Piltin
GAGretchen M.D Ahrendt
Gretchen M.D Ahrendt
JBJudy C. Boughey
Judy C. Boughey
Neoadjuvant chemotherapy (NAC) increases rates of successful breast-conserving surgery (BCS) in patients with breast cancer. However, some studies suggest that BCS after NAC may confer an increased risk of locoregional recurrence (LRR). We assessed LRR rates and locoregional recurrence-free survival (LRFS) in patients enrolled on I-SPY2 (NCT01042379), a prospective NAC trial for patients with clinical stage II to III, molecularly high-risk breast cancer. Cox proportional hazards models were used to evaluate associations between surgical procedure (BCS vs mastectomy) and LRFS adjusted for age, tumor receptor subtype, clinical T category, clinical nodal status, and residual cancer burden (RCB). In 1462 patients, surgical procedure was not associated with LRR or LRFS on either univariate or multivariate analysis. The unadjusted incidence of LRR was 5.4% after BCS and 7.0% after mastectomy, at a median follow-up time of 3.5 years. The strongest predictor of LRR was RCB class, with each increasing RCB class having a significantly higher hazard ratio for LRR compared with RCB 0 on multivariate analysis. Triple-negative receptor subtype was also associated with an increased risk of LRR (hazard ratio: 2.91, 95% CI: 1.8–4.6, P < 0.0001), regardless of the type of operation. In this large multi-institutional prospective trial of patients completing NAC, we found no increased risk of LRR or differences in LRFS after BCS compared with mastectomy. Tumor receptor subtype and extent of residual disease after NAC were significantly associated with recurrence. These data demonstrate that BCS can be an excellent surgical option after NAC for appropriately selected patients.

14 September 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KKKatia Khoury
Katia Khoury
JMJane L. Meisel
Jane L. Meisel
CYChristina Yau
Christina Yau
HRHope Rugo
Hope Rugo
RNRita Nanda
Rita Nanda
LELaura J. Esserman
Laura J. Esserman

19 December 2019 in Clinical Breast Cancer
Verified
Journal Article
Closed access
CSCandice Sauder
Candice Sauder
SBSarah B. Bateni
Sarah B. Bateni
ADAnders J. Davidson
Anders J. Davidson
DNDaniel K. Nishijima
Daniel K. Nishijima